miR‐134 inhibits non‐small cell lung cancer growth by targeting the epidermal growth factor receptor |
| |
Authors: | Qin Qin Furong Wei Jianbo Zhang Xingwu Wang Baosheng Li |
| |
Affiliation: | 1. Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong University, Jinan, China;2. Department of Radiation Oncology (Chest Section), Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, China;3. Institute of Basic Medicine, Shandong Academy of Medical Sciences, School of Medicine and Life Sciences, University of Jinan‐Shandong Academy of Medical Sciences, Jinan, China;4. Department of Pathology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, China;5. Basic Research Center, Shandong Cancer Hospital and Institute, Shandong University, Jinan, China |
| |
Abstract: | The epidermal growth factor receptor (EGFR) is frequently activated in a wide range of solid tumours and represents an important therapeutic target. MicroRNAs (miRNAs) have recently been recognized as a rational and potential modality for anti‐EGFR therapies. However, more EGFR‐targeting miRNAs need to be explored. In this study, we identified a novel EGFR‐targeting miRNA, miRNA‐134 (miR‐134), in non‐small‐cell lung cancer (NSCLC) cell lines. Luciferase assays confirmed that EGFR is a direct target of miR‐134. In addition, the overexpression of miR‐134 inhibited EGFR‐related signaling and suppressed NSCLC cells proliferation by inducing cell cycle arrest and/or apoptosis, suggesting that miR‐134 functions as a tumour suppressor in NSCLC. Further mechanistic investigation including RNAi and rescue experiments suggested that the down‐regulation of EGFR by miR‐134 partially contributes to the antiproliferative role of miR‐134. Last, in vivo experiments demonstrated that miR‐134 suppressed tumour growth of A549 xenograft in nude mice. Taken together, our findings suggest that miR‐134 inhibits non‐small cell lung cancer growth by targeting the EGFR. |
| |
Keywords: |
EGFR
non‐small cell lung cancer miR‐134 tumour suppressor |
|
|